| Patient | Donor and graft | conditioning | GVHD prophylaxis | GVHD | donor chimerism at last f/u |
|---|---|---|---|---|---|
| 1 | MUD (10/10) |
Fludarabine 6x30 mg/m2 Busulfan tAUC 53770 ng x h/ml Alemtuzumab 3x0.2 mg/kg |
CSA/MMF | aGVHD °I (skin) | >95% |
| 2 | MUD (9/10) |
Fludarabine 5x30 mg/m2 Treosulfan 3x14.000 mg/m2 Thiotepa 2x5 mg/kg Alemtuzumab 4x0.2 mg/kg |
CSA/MMF | aGVHD °I (skin) | 100% |
| 3 | MSD (10/10) |
Fludarabine 5x30 mg/m2 Treosulfan 3x14.000 mg/m2 Thiotepa 2x5mg/kg ATG 3x10mg/kg |
CSA/MMF | aGVHD °I (skin) | 100% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.